Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

A prospective study of health care resource utilisation and selected costs of schizophrenia in France.

Sarlon E, Heider D, Millier A, Azorin JM, König HH, Hansen K, Angermeyer MC, Aballéa S, Toumi M.

BMC Health Serv Res. 2012 Aug 21;12:269-76.

2.

Economic burden of schizophrenia: empirical analyses from a survey in Thailand.

Phanthunane P, Whiteford H, Vos T, Bertram M.

J Ment Health Policy Econ. 2012 Mar;15(1):25-32.

PMID:
22611090
3.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
4.

An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach.

Vázquez-Polo FJ, Negrín M, Cabasés JM, Sánchez E, Haro JM, Salvador-Carulla L.

J Ment Health Policy Econ. 2005 Sep;8(3):153-65.

PMID:
16278503
5.

Health costs in anthroposophic therapy users: a two-year prospective cohort study.

Hamre HJ, Witt CM, Glockmann A, Ziegler R, Willich SN, Kiene H.

BMC Health Serv Res. 2006 Jun 2;6:65.

6.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
7.

Health care resource use associated with integrated psychological treatment.

Vasiliadis HM, Briand C, Lesage A, Reinharz D, Stip E, Nicole L, Lalonde P.

J Ment Health Policy Econ. 2006 Dec;9(4):201-7.

PMID:
17200597
8.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

9.

The societal cost of schizophrenia in Sweden.

Ekman M, Granstrom O, Omerov S, Jacob J, Landen M.

J Ment Health Policy Econ. 2013 Mar;16(1):13-25.

PMID:
23676412
10.

The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.

Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M, Toso V.

BMC Neurol. 2012 Nov 14;12:137. doi: 10.1186/1471-2377-12-137.

11.

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, Testori A, Bédane C, Konto C, Dueymes A, Sbarigia U, van Baardewijk M.

Eur J Cancer. 2012 Sep;48(14):2175-82. doi: 10.1016/j.ejca.2012.03.003. Epub 2012 Apr 3.

PMID:
22480965
12.

Home treatment for mental health problems: a systematic review.

Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, Wright C.

Health Technol Assess. 2001;5(15):1-139. Review.

13.

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe.

Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, Nordmann JP, Renard JP, Bayer A, Grehn F, Pfeiffer N, Cedrone C, Gandolfi S, Orzalesi N, Nucci C, Rossetti L, Azuara-Blanco A, Bagnis A, Hitchings R, Salmon JF, Bricola G, Buchholz PM, Kotak SV, Katz LM, Siegartel LR, Doyle JJ.

Br J Ophthalmol. 2005 Oct;89(10):1245-9.

14.

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.

Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, Argimon JM, Bruno G, Novick D, Vellas B, Haro JM.

J Alzheimers Dis. 2013;36(2):385-99. doi: 10.3233/JAD-122392.

PMID:
23629588
15.

Direct costs of schizophrenia in Italian community psychiatric services.

Garattini L, Rossi C, Tediosi F, Cornaggia C, Covelli G, Barbui C, Parazzini F.

Pharmacoeconomics. 2001;19(12):1217-25.

PMID:
11772157
16.

[Health related quality of life and disease burden of patients with schizophrenia in Hungary].

Péntek M, Harangozó J, Egerházi A, Kelemen O, Gulácsi L, Baji P, Máttyássy A, Erdélyi R, Lehoczky S, Orlewska E, Vártokné Hevér N, Ferencz A, Brodszky V.

Psychiatr Hung. 2012;27(1):4-17. Hungarian.

PMID:
22493145
17.

Substitution of doctors by nurses in primary care.

Laurant M, Reeves D, Hermens R, Braspenning J, Grol R, Sibbald B.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001271. Review.

PMID:
15846614
18.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
19.

Cost of schizophrenia: direct costs and use of resources in the State of São Paulo.

Leitão RJ, Ferraz MB, Chaves AC, Mari JJ.

Rev Saude Publica. 2006 Apr;40(2):304-9. Epub 2006 Mar 29.

20.

Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE).

Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, Dinsmore J, Floyd S, Hoadley A, Johnson T, Kalaitzaki E, King M, Leurent B, Maratos A, O'Neill FA, Osborn D, Patterson S, Soteriou T, Tyrer P, Waller D; MATISSE project team.

Health Technol Assess. 2012;16(8):iii-iv, 1-76. doi: 10.3310/hta16080.

Supplemental Content

Support Center